trending Market Intelligence /marketintelligence/en/news-insights/trending/nccrsa2FaxB_awRR0WTPcg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

GSK issues tender offer for outstanding shares of Tesaro as part of $5.1B deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

GSK issues tender offer for outstanding shares of Tesaro as part of $5.1B deal

GlaxoSmithKline PLC has issued a tender offer for all of the outstanding shares of Tesaro Inc. for $75 apiece as the U.K.'s biggest pharmaceuticals company acquires the Waltham, Mass.-based biotechnology company.

GSK on Dec. 3 announced plans to buy the U.S.-based cancer drug developer for $5.1 billion. Tesaro's main product is Zejula, which is approved in the U.S. and Europe for ovarian cancer.

Tesaro has yet to file a statement with a recommendation of its directors for stockholders to submit their shares in the offer, which began Dec. 14 and will end Jan. 14, 2019.

Following the completion of the offer, GSK unit Adriatic Acquisition will acquire all remaining shares through a merger. The transaction, which includes the offer and merger, is subject to the approval of Tesaro's stockholders and other closing conditions.

According to GlaxoSmithKline, stockholders owning 25.7% of all issued and outstanding shares of Tesaro have already agreed to submit their shares in the offer as of Dec. 10.